ENTX on Nasdaq

Entera Bio Ltd.

Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies.1

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Calidi Biotherapeutics, Inc., Inmune Bio, Inc. or BioCardia, Inc., or pick any stock.

  • TickerENTX on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersL31
  • Incorporated inIsrael2
  • Business addressKiryat Hadassah, Minrav Building, Fifth Floor, Jerusalem, 91120022
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

0.0%Gross margin4
-27450.0%Operating margin4
-27235.7%Net margin4
-76.8%Revenue growth, 20254
-87.3%Return on equity4
-$7.5MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue1¢$42.0K
  • Research and development93¢$6.0M
  • Selling, general and admin6¢$398.0K

Out of $42.0K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$42.0K in 2025−82% since 2019
0$200.0K$400.0K$600.0K2019: $236.0K$236.0K20192020: $365.0K$365.0K2020+55%2021: $571.0K$571.0K2021+56%2022: $134.0K$134.0K2022−77%2023: $0$020232024: $181.0K$181.0K20242025: $42.0K$42.0K2025−77%
Gross profit67894$0 in 2025
0$50.0K$100.0K$150.0K$200.0K2020: $65.0K$65.0K20202021: $198.0K$198.0K2021+205%2022: $33.0K$33.0K2022−83%2023: $0$020232024: $9.0K$9.0K20242025: $0$02025
Operating income567894-$11.5M in 2025+1% since 2019
-$15.0M-$10.0M-$5.0M02019: -$11.5M-$11.5M20192020: -$11.2M-$11.2M2020−2%2021: -$12.2M-$12.2M2021+9%2022: -$13.0M-$13.0M2022+7%2023: -$8.9M-$8.9M2023−32%2024: -$9.6M-$9.6M2024+8%2025: -$11.5M-$11.5M2025+20%
Net income567894-$11.4M in 2025+6% since 2019
-$15.0M-$10.0M-$5.0M02019: -$10.8M-$10.8M20192020: -$11.2M-$11.2M2020+4%2021: -$12.2M-$12.2M2021+9%2022: -$13.1M-$13.1M2022+7%2023: -$8.9M-$8.9M2023−32%2024: -$9.5M-$9.5M2024+7%2025: -$11.4M-$11.4M2025+20%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
REVENUES$42.0K$181.0K
COST OF REVENUES$42.0K$172.0K
GROSS PROFIT$0$9.0K
Research and development, net$6.0M$4.5M
General and administrative$5.5M$5.1M
TOTAL OPERATING EXPENSES$11.5M$9.6M
OPERATING LOSS$11.5M$9.6M
FINANCIAL INCOME, NET-$90.0K-$58.0K
LOSS BEFORE INCOME TAX$11.4M$9.5M
INCOME TAX EXPENSES$0$14.0K
NET LOSS$11.4M$9.5M
LOSS PER SHARE BASIC$0.25$0.25
LOSS PER SHARE DILUTED$0.25$0.25
WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE46.2M shares37.7M shares
WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE46.2M shares37.7M shares

Compare Entera Bio Ltd. with another company

Leadership

Who has led Entera Bio Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Spiros Jamas2022
  2. Miranda Jayne Toledano2022–now

Chief financial officer

  1. Ramesh Ratan2022
  2. Dana Yaacov-Garbeli2022–now

Chief operating officer

  1. Hillel Galitzer2022–now
2025
Board members and other officers (14)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorSteven D. Rubin named Aug 12, 202630

Timeline

  1. Sep 9, 2022New chief executive Miranda Jayne Toledano becomes CEO13
  2. Jan 20, 2022New chief executive Spiros Jamas becomes CEO12

Filings

279 filings to the SEC since October 2021: 6 annual reports, 14 quarterly reports, 50 major events, 126 insider forms, 17 large holders, 2 private raises, 64 other. The latest 20:

  1. Oct 14, 2026DEF 14A EDGAR
  2. Oct 6, 20268-K EDGAR
  3. Sep 23, 2026PRE 14A EDGAR
  4. Aug 28, 2026EFFECT EDGAR
  5. Aug 28, 2026424B3 EDGAR
  6. Aug 21, 2026S-3 EDGAR
  7. Aug 21, 20263 EDGAR
  8. Aug 18, 20268-K EDGAR
  9. Aug 12, 2026D EDGAR
  10. Aug 7, 20264 EDGAR
  11. Aug 7, 20264 EDGAR
  12. Aug 7, 20264 EDGAR
  13. Aug 7, 20264 EDGAR
  14. Aug 7, 20264 EDGAR
  15. Aug 7, 20264 EDGAR
  16. Aug 7, 20264 EDGAR
  17. Aug 7, 20264 EDGAR
  18. Aug 7, 20264 EDGAR
  19. Aug 7, 2026S-8 EDGAR
  20. Aug 7, 202610-Q EDGAR

The 279 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

32 open-market trades by officers, directors and large owners since October 2021: 32 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 9, 2026Germano Geno JDirectorBuy20,000$1.30$26.0KForm 4
Mar 5, 2026Ellis SeanDirectorBuy10,000$1.23$12.3KForm 4
Feb 12, 2026Rubin Steven DDirectorBuy5,000$1.49$7.5KForm 4
Feb 10, 2026Taitel HayaDirectorBuy7,500$1.48$11.1KForm 4
Feb 10, 2026Germano Geno JDirectorBuy20,000$1.49$29.8KForm 4
Feb 9, 2026Rubin Steven DDirectorBuy10,000$1.20$12.0KForm 4
Feb 9, 2026Ellis SeanDirectorBuy18,000$1.24$22.3KForm 4
Dec 29, 2025Toledano Miranda JayneChief Executive OfficerBuy11,000$1.81$19.9KForm 4
Jan 12, 2024Taitel HayaDirectorBuy9,500$0.99$9.4KForm 4
Jan 10, 2024Taitel HayaDirectorBuy7,615$0.77$5.9KForm 4
Dec 22, 2023LIEBERMAN GERALD MDirectorBuy23,952$0.71$17.0KForm 4
Dec 22, 2023Toledano Miranda JayneChief Executive OfficerBuy23,952$0.71$17.0KForm 4
Aug 22, 2023Taitel HayaDirectorBuy18,000$0.62$11.2KForm 4
Aug 21, 2023LIEBERMAN GERALD MDirectorBuy20,000$0.59$11.8KForm 4
Aug 21, 2023Ellis SeanDirectorBuy40,000$0.60$24.0KForm 4
Apr 4, 2023Toledano Miranda JayneChief Executive OfficerBuy30,000$1.01$30.3KForm 4
Nov 14, 2022Yaacov-Garbeli DanaChief Financial OfficerBuy26,580$0.54$14.4KForm 4
Nov 14, 2022LIEBERMAN GERALD MDirectorBuy50,000$0.57$28.5KForm 4
Nov 11, 2022Yaacov-Garbeli DanaChief Financial OfficerBuy30,000$0.52$15.6KForm 4
Nov 11, 2022Ellis SeanDirectorBuy30,000$0.53$15.9KForm 4

All 32 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 28, 2026Raised $275 million in a private offering of equity Form D: 53 investors so far Form D
  2. Dec 20, 2023Raised $6.6 million in a private offering of equity Form D: 52 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40